Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Total Liabilities (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Total Liabilities for 15 consecutive years, with $921000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 11.5% year-over-year to $921000.0, compared with a TTM value of $921000.0 through Sep 2025, up 11.5%, and an annual FY2024 reading of $692000.0, down 64.62% over the prior year.
  • Total Liabilities was $921000.0 for Q3 2025 at Alaunos Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $45.1 million in Q3 2021 and bottomed at $692000.0 in Q4 2024.
  • Average Total Liabilities over 5 years is $15.5 million, with a median of $6.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 114.79% in 2021, then plummeted 93.52% in 2024.
  • Year by year, Total Liabilities stood at $36.8 million in 2021, then fell by 28.33% to $26.4 million in 2022, then tumbled by 92.59% to $2.0 million in 2023, then plummeted by 64.62% to $692000.0 in 2024, then skyrocketed by 33.09% to $921000.0 in 2025.
  • Business Quant data shows Total Liabilities for TCRT at $921000.0 in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.